Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
| Autor: | Lucie Blondeau, Michelle Samuel, Nadia Bouabdallaoui, Paul Khairy, Jean-Claude Tardif, Marie-Pierre Dubé, Marie-Claude Guertin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Acute coronary syndrome
medicine.medical_specialty 030204 cardiovascular system & hematology Placebo law.invention Coronary artery disease 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Secondary Prevention medicine Humans 030212 general & internal medicine Myocardial infarction Stroke Randomized Controlled Trials as Topic business.industry Hazard ratio medicine.disease Cardiovascular Diseases Meta-analysis Colchicine Cardiology and Cardiovascular Medicine business |
| Zdroj: | Canadian Journal of Cardiology. 37:776-785 |
| ISSN: | 0828-282X |
| DOI: | 10.1016/j.cjca.2020.10.006 |
| Popis: | Background Reduction of inflammation with colchicine has emerged as a therapeutic option for secondary prevention of cardiovascular disease (CVD) in patients with coronary artery disease (CAD). Our objective was to consolidate evidence from randomized controlled trials (RCTs) evaluating the efficacy and safety of low-dose colchicine for secondary prevention of CVD among patients with CAD on standard medical therapy. Methods RCTs comparing the incidence of cardiovascular (CV) events between patients with clinically manifest CAD randomized to colchicine vs placebo (or no colchicine) were included. The primary composite efficacy endpoint included CV mortality, myocardial infarction (MI), ischemic stroke, and urgent coronary revascularization. The DerSimonian and Laird random-effects model was used to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Results Four RCTs, with a pooled sample size of 11,594 patients, were included (colchicine n = 5774; placebo/no colchicine n = 5820). Included RCTs studied populations with stable CAD (N = 2) and acute coronary syndrome (N = 2). Compared with placebo or no colchicine, colchicine was associated with a statistically significant reduction in the incidence of the primary composite endpoint (pooled HR, 0.68; 95% CI, 0.54-0.81; I2 = 37.7%). The reduction in CV events among patients randomized to colchicine was driven by statistically significant reductions in MIs, ischemic strokes, and urgent coronary revascularizations (P 0.05). Conclusions In secondary prevention of CV events, the addition of low-dose colchicine to standard medical therapy reduces the incidence of major CV events—except CV mortality—when compared with standard medical therapy alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect